Highest-materiality recent filing
BioVie raises ~$12M gross in public offering of units (stock + warrants) at $2.00/unit
Gross proceeds ~$12M from 6M units (5.62M shares + 380K pre-funded) at $2.00/unit.
BioVie board effectuates 1-for-10 reverse stock split effective July 7, 2025
Reverse stock split ratio of 1-for-10 becomes effective at 12:01 am ET on July 7, 2025.
BioVie prices $3.2M registered direct offering of 1.146M shares at $2.83/share
Offering of 1,146,000 shares at $2.83 per share, gross proceeds ~$3.2M.
BioVie closes registered direct offering raising $3.24M gross proceeds at $2.83/share
Closed registered direct offering of 1,146,000 shares at $2.83/share, gross proceeds ~$3.24M.
BioVie prices $6.0M registered direct offering at $2.25/share; issues warrants at $2.12
Gross proceeds of ~$6,000,750 from 2,667,000 shares of common stock at $2.25 per share.
BioVie closes $6M registered direct offering of 2.67M shares at $2.25/share with warrants
Closed offering of 2,667,000 shares at $2.25 per share for gross proceeds of $6,000,750.
BioVie prices $6.66M registered direct offering of 4.44M shares at $1.50/share
Gross proceeds of ~$6.66M from sale of 4,443,000 shares at $1.50/share in registered direct offering.
BioVie closes registered direct offering of 4.44M shares at $1.50, raising $6.66M gross
Closed registered direct offering of 4,443,000 shares at $1.50/share for gross proceeds of $6,664,500.
BioVie closes $3M public offering of shares and warrants at $1.53/unit
Closed best efforts offering of 1,360,800 shares, pre-funded warrants for 600,000 shares, and 1,960,800 common warrants.
BioVie prices $3M public offering of 1.96M units at $1.53/share with warrants
Gross proceeds ~$3M from 1,960,800 units at $1.53 each; each unit includes share or pre-funded warrant plus 5-year warrant exercisable at $1.53.
BioVie receives Nasdaq delisting notice; has 180 days to regain compliance
Nasdaq notified BioVie that its stock closed below $1.00 for 30 consecutive business days.
BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025
Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.
BioVie closes ~$21M public offering of stock and warrants
Issued 15M shares, pre-funded warrants for 6M shares, and common warrants for 10.5M shares at $1.00 combined price.
BioVie announces $21M public offering of 21M shares at $1.00 with warrants
Offering of 21,000,000 common shares (or pre-funded warrants) at $1.00 per share, plus warrants to purchase up to 10,500,000 shares at $1.50.
PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.
BioVie hit with shareholder class action over NE3107 trial disclosures
Lawsuit filed Jan 19, 2024 in Nevada federal court (Olmstead v. BioVie Inc., No. 3:24-cv-00035).
BioVie files prospectus supplement for up to $25M ATM; already raised $59.4M from 8.1M shares
Filed prospectus supplement under new shelf registration (333-274083) for continued at-the-market sales of common stock.
BioVie Phase 3 NE3107 Alzheimer's trial misses primary endpoint; positive per-protocol trends
Primary endpoint missed statistical significance due to exclusion of patients from 15 sites with GCP violations; sites referred to FDA.
BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed
Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.
On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.
On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material